Seeing is believing: eye drops for cataracts

Article

A company in the US, Chakshu Research, claims that it has developed an eye drop that can remove cataracts and restore vision.

A company in the US, Chakshu Research, claims that it has developed an eye drop that can remove cataracts and restore vision.

The company recently completed early clinical trials at several academic centers around the US, including Johns Hopkins University, Harvard University and the University of Utah. It is about to launch Phase II/III trials early next year, and is partnering with researchers at the University of Texas at Galveston.

Its product, tentatively called C-KAD, targets the 50-plus market that is projected to reach $2 billion in annual revenue and possibly more with the rapid aging of the baby boomer demographic.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.